Markets
Bicara Stock Soars 9% After Results — Its Cash Runway Extends Into Early 2029
The cancer-drug developer's quarterly loss widened as trial and staffing costs rose, with pivotal trial results expected in mid-2027.
Bicara Therapeutics (BCAX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The cancer-drug developer's quarterly loss widened as trial and staffing costs rose, with pivotal trial results expected in mid-2027.
Earnings
Management defended its trial size and potential approval timing as analysts pressed on the evidence needed to compete.
SEC Filings
The experimental cancer-drug developer expects its $442.3 million in cash and investments to cover operations into the first half of 2029.